Featured Research

from universities, journals, and other organizations

Wake Forest Scientists Find Way To Short-Circuit Initial HIV Invasion

Date:
October 14, 1997
Source:
Bowman Gray/Baptist Hospital Medical Center
Summary:
Scientists at Wake Forest University Baptist Medical Center report today that they have found another way to shut down the doorway for HIV-1 to invade two types of white blood cells --lymphocytes and macrophages.

WINSTON-SALEM -- Scientists at Wake Forest University Baptist MedicalCenter report today that they have found another way to shut down the doorwayfor HIV-1 to invade two types of white blood cells -- lymphocytes andmacrophages.

Related Articles


In a report in the Oct 14 issue of the Proceedings of the NationalAcademy of Sciences, Si.-Yi Chen, M.D., Ph.D., assistant professor of cancerbiology, and his colleagues describe how they have inactivated the mostfrequently used co-receptor -- docking site -- for HIV-1 viruses on the surfaceof both macrophages and lymphocytes, resulting in immunity of those macrophagesand lymphocytes to HIV-1 infection.

This co-receptor is called CCR5 and serves as the doorway or dockingsite for early-stage HIV-1 virus, known scientifically as macrophage tropic (orM-tropic) virus.

Two weeks ago, the same team reported in Nature Medicine that they hadfound a way to inactivate a different co-receptor -- CXCR4 -- which is thedocking site for late stage HIV-1 virus, known medically as T-cell tropic virus.

Based upon HIV-1 infectivity, HIV-1 viruses are classified as M-tropicor T-cell tropic. During the period soon after HIV-1 infection when mostpatients have no symptoms, most HIV-1 viruses are M-tropic, and use the CCR5co-receptor for entry into lymphocytes and macrophages.

In the late stage of AIDS, HIV-1 viruses change their infectivity toT-cell tropic, and use the CXCR4 receptor to get into the lymphocytes. Soblocking entry of that type of virus into the cell blocks the late stages ofAIDS.

The approach described in Nature Medicine could be utilized to treatAIDS patients and late stage HIV-1-infected individuals, while the approachdescribed in Proceedings could be used to treat early-stage of HIV-infectedindividuals and may be some day be used to prevent HIV-1 infection.

For both instances, Chen and his colleagues designed a novel approach,termed "intracellular chemokine" -- intrakine for short -- to geneticallyinactivate the chemokine co-receptor.

In the report in Proceedings, Chen and his colleagues described how theyused an intrakine called RANTES-intrakine to successfully inactivate the CCR5co-receptor for the macrophage-tropic HIV-1 viruses..

The SDF-intrakine described in Nature Medicine genetically inactivatesthe CXCR4 co-receptor. The SDF-intrakine binds to the CXCR4 and traps themolecules inside the lymphocyte, leaving the T-cell tropic HIV-1 with no placeto dock.

Chen said that the intrakine approach avoids technical problems facingmany current gene therapy approaches.

"This intrakine approach is especially well suited to be translatedinto clinical practice," Chen said, noting that on a typical macrophage orlymphocytes, there are few CCR5 co-receptors, which means that the task ofinactivating the CCR5 can be achievable by current available gene therapytechnology. Intrakines are human derivatives, and not foreign to human.

In treating people with HIV infection, Chen envisions that in the nearfuture, human macrophages and lymphocytes from an infected patient's peripheralblood can be genetically modified with the appropriate intrakine, andperiodically reinfused back into patients to delay the disease progression.

Ultimately, Chen said he hoped that stem cells, the mother cells of allimmune cells with an unlimited capability of proliferation, can be geneticallymodified with the intrakine, and reinfused back into patients to regenerate anew immune system that is resistant to HIV-1 infection.

His group is now in the stage of pre-clinical study to further evaluatethe efficacy and safety of this intrakine approach, and clinical trials inhumans are a year or more away.

The Proceedings article was edited by Anthony S. Fauci, M.D., directorof the National Institute of Allergy and Infectious Diseases of NIH, and and amember of the editorial board. The research scientists in Chen's team includeAn-gang Yang, M.D., Ph.D. a post-doctoral fellow, Xuefai Bai, Ph.D., a researchfellow, and Xue F. Huang, Ph.D. a research fellow.


Story Source:

The above story is based on materials provided by Bowman Gray/Baptist Hospital Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Bowman Gray/Baptist Hospital Medical Center. "Wake Forest Scientists Find Way To Short-Circuit Initial HIV Invasion." ScienceDaily. ScienceDaily, 14 October 1997. <www.sciencedaily.com/releases/1997/10/971014043829.htm>.
Bowman Gray/Baptist Hospital Medical Center. (1997, October 14). Wake Forest Scientists Find Way To Short-Circuit Initial HIV Invasion. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/1997/10/971014043829.htm
Bowman Gray/Baptist Hospital Medical Center. "Wake Forest Scientists Find Way To Short-Circuit Initial HIV Invasion." ScienceDaily. www.sciencedaily.com/releases/1997/10/971014043829.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins